(134 days)
No
The summary describes a physical interbody fusion device made of titanium, with no mention of software, algorithms, or data processing that would indicate the use of AI/ML.
Yes
The device is an interbody fusion device intended for anterior cervical interbody fusion procedures to treat degenerative disc disease and facilitate spinal fusion.
No
This device is an interbody fusion implant, not a diagnostic device. It is used to facilitate spinal fusion in patients with degenerative disc disease, which is a treatment, not a diagnosis.
No
The device description explicitly states that the system is comprised of interbodies, plates, and screws, which are physical hardware components made of titanium alloy.
No, this device is not an IVD (In Vitro Diagnostic).
Here's why:
- IVD Definition: In Vitro Diagnostics are devices intended for use in the collection, preparation, and examination of specimens taken from the human body (such as blood, urine, or tissue) to provide information for the diagnosis, prevention, or treatment of a disease or condition.
- Device Description: The CYLOX® ST implants are physical implants designed to be surgically placed in the cervical spine to facilitate bone fusion. They are structural devices, not devices used for testing biological samples.
- Intended Use: The intended use clearly states that the device is for "anterior cervical interbody fusion procedures" in patients with degenerative disc disease. This is a surgical treatment, not a diagnostic test.
The provided information describes a medical device used for surgical intervention, not for in vitro diagnostic testing.
N/A
Intended Use / Indications for Use
The CYLOX® ST implants are interbody fusion devices intended for anterior cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies.
The cervical device is to be used in patients who have had at least six (6) weeks of non-operative treatment. The devices are to be used with autograft bone graft composed of cancellous, cortical, and / or corticocancellous bone and implanted via an anterior approach.
When used as a standalone system, CYLOX® ST is intended to be used as an adjunct to spinal fusion procedures at one level (C3-T1) and must be used with the CYLOX® ST bone screw fixation or connecting plate and must be secured with the corresponding locking screw.
When used with supplemental fixation, such as anterior cervical plates, CYLOX® ST is intended to be used as an adjunct to spinal fusion procedures at one or two levels of the cervical spine (C3-T1).
Product codes
OVE, ODP
Device Description
The SIGNUS CYLOX® ST Interbody System is an anterior cervical intervertebral body fusion system. The system is comprised of interbodies, plates, and screws. The interbody device can be used as a standalone implant with screw holes for integrated fixation, or as a construct fixed with a plate and screws. The interbody implants are additively manufactured from titanium alloy (Ti-6Al-4 V ELI). The plates and screws are traditionally machined from titanium alloy (Ti-6Al-4V).
The SIGNUS CYLOX® ST Interbody System is placed in the C3 – T1 spinal region via the Cloward or Smith-Robinson approach. The interbody is available in four different footprints, with multiple heights and angulations. The standalone interbody contains a central holes angulated for fixation with screws into the cranial and caudal vertebral body. The construct interbody contains a central hole and indentation features to mate with the anterior plate.
The device is comprised of structural titanium in an open-pore grid structure. The large fenestration in the implant permits the cage to be packed with autogenous bone graft and/or allograft comprised of cancellous and/or corticocancellous bone graft to facilitate fusion.
Mentions image processing
Not Found
Mentions AI, DNN, or ML
Not Found
Input Imaging Modality
Not Found
Anatomical Site
cervical spine (C3-T1)
Indicated Patient Age Range
skeletally mature patients
Intended User / Care Setting
Not Found
Description of the training set, sample size, data source, and annotation protocol
Not Found
Description of the test set, sample size, data source, and annotation protocol
Not Found
Summary of Performance Studies (study type, sample size, AUC, MRMC, standalone performance, key results)
Substantial equivalence was supported by the results of verification testing to confirm that features, geometry and performance of the subject device performs as well as the predicate system, including:
- Static Axial Compression per ASTM F2077-22 .
- Static Axial Compression Shear per ASTM F2077-22
- . Static Axial Torsion per ASTM F2077-22
- . Dynamic Axial Compression per ASTM F2077-22
- . Dynamic Axial Compression Shear per ASTM F2077-22
- . Dynamic Axial Torsion per ASTM F2077-22
- . Static Expulsion per ASTM F-04.25.02.02
- . Static Subsidence per ASTM F2267-22
Key Metrics (Sensitivity, Specificity, PPV, NPV, etc.)
Not Found
Predicate Device(s)
Reference Device(s)
Predetermined Change Control Plan (PCCP) - All Relevant Information
Not Found
§ 888.3080 Intervertebral body fusion device.
(a)
Identification. An intervertebral body fusion device is an implanted single or multiple component spinal device made from a variety of materials, including titanium and polymers. The device is inserted into the intervertebral body space of the cervical or lumbosacral spine, and is intended for intervertebral body fusion.(b)
Classification. (1) Class II (special controls) for intervertebral body fusion devices that contain bone grafting material. The special control is the FDA guidance document entitled “Class II Special Controls Guidance Document: Intervertebral Body Fusion Device.” See § 888.1(e) for the availability of this guidance document.(2) Class III (premarket approval) for intervertebral body fusion devices that include any therapeutic biologic (e.g., bone morphogenic protein). Intervertebral body fusion devices that contain any therapeutic biologic require premarket approval.
(c)
Date premarket approval application (PMA) or notice of product development protocol (PDP) is required. Devices described in paragraph (b)(2) of this section shall have an approved PMA or a declared completed PDP in effect before being placed in commercial distribution.
0
February 11, 2025
Image /page/0/Picture/1 description: The image shows the logo of the U.S. Food and Drug Administration (FDA). On the left is the Department of Health & Human Services logo. To the right of that is the FDA logo, which is a blue square with the letters "FDA" in white. To the right of the FDA logo is the text "U.S. FOOD & DRUG ADMINISTRATION" in blue.
SIGNUS Medizintechnik GmbH % Emily Szabo Quality & Regulatory Engineer JALEX Medical, LLC 27865 Clemens Road. Suite 3 Westlake, Ohio 44145
Re: K243188
Trade/Device Name: CYLOX® ST Regulation Number: 21 CFR 888.3080 Regulation Name: Intervertebral Body Fusion Device Regulatory Class: Class II Product Code: OVE, ODP Dated: September 30, 2024 Received: December 19, 2024
Dear Emily Szabo:
We have reviewed your section 510(k) premarket notification of intent to market the device referenced above and have determined the device is substantially equivalent (for the indications for use stated in the enclosure) to legally marketed predicate devices marketed in interstate commerce prior to May 28, 1976, the enactment date of the Medical Device Amendments, or to devices that have been reclassified in accordance with the provisions of the Federal Food, Drug, and Cosmetic Act (the Act) that do not require approval of a premarket approval application (PMA). You may, therefore, market the device, subject to the general controls provisions of the Act. Although this letter refers to your product as a device, please be aware that some cleared products may instead be combination products. The 510(k) Premarket Notification Database available at https://www.accessdata.fda.gov/scripts/cdrh/cfdocs/cfpmn/pmn.cfm identifies combination product submissions. The general controls provisions of the Act include requirements for annual registration, listing of devices, good manufacturing practice, labeling, and prohibitions against misbranding and adulteration. Please note: CDRH does not evaluate information related to contract liability warranties. We remind you, however, that device labeling must be truthful and not misleading.
If your device is classified (see above) into either class II (Special Controls) or class III (PMA), it may be subject to additional controls. Existing major regulations affecting your device can be found in the Code of Federal Regulations, Title 21, Parts 800 to 898. In addition, FDA may publish further announcements concerning your device in the Federal Register.
Additional information about changes that may require a new premarket notification are provided in the FDA guidance documents entitled "Deciding When to Submit a 510(k) for a Change to an Existing Device"
1
(https://www.fda.gov/media/99812/download) and "Deciding When to Submit a 510(k) for a Software Change to an Existing Device" (https://www.fda.gov/media/99785/download).
Your device is also subject to, among other requirements, the Quality System (QS) regulation (21 CFR Part 820), which includes, but is not limited to, 21 CFR 820.30. Design controls; 21 CFR 820.90. Nonconforming product; and 21 CFR 820.100, Corrective and preventive action. Please note that regardless of whether a change requires premarket review. the OS regulation requires device manufacturers to review and approve changes to device design and production (21 CFR 820.30 and 21 CFR 820.70) and document changes and approvals in the device master record (21 CFR 820.181).
Please be advised that FDA's issuance of a substantial equivalence determination does not mean that FDA has made a determination that your device complies with other requirements of the Act or any Federal statutes and regulations administered by other Federal agencies. You must comply with all the Act's requirements, including, but not limited to: registration and listing (21 CFR Part 807); labeling (21 CFR Part 801); medical device reporting of medical device-related adverse events) (21 CFR Part 803) for devices or postmarketing safety reporting (21 CFR Part 4, Subpart B) for combination products (see https://www.fda.gov/combination-products/guidance-regulatory-information/postmarketing-safety-reportingcombination-products); good manufacturing practice requirements as set forth in the quality systems (QS) regulation (21 CFR Part 820) for devices or current good manufacturing practices (21 CFR Part 4, Subpart A) for combination products; and, if applicable, the electronic product radiation control provisions (Sections 531-542 of the Act); 21 CFR Parts 1000-1050.
All medical devices, including Class I and unclassified devices and combination product device constituent parts are required to be in compliance with the final Unique Device Identification System rule ("UDI Rue"). The UDI Rule requires, among other things, that a device bear a unique device identifier (UDI) on its label and package (21 CFR 801.20(a)) unless an exception or alternative applies (21 CFR 801.20(b)) and that the dates on the device label be formatted in accordance with 21 CFR 801.18. The UDI Rule (21 CFR 830.300(a) and 830.320(b)) also requires that certain information be submitted to the Global Unique Device Identification Database (GUDID) (21 CFR Part 830 Subpart E). For additional information on these requirements, please see the UDI System webpage at https://www.fda.gov/medical-devices/device-advicecomprehensive-regulatory-assistance/unique-device-identification-system-udi-system.
Also, please note the regulation entitled, "Misbranding by reference to premarket notification" (21 CFR 807.97). For questions regarding the reporting of adverse events under the MDR regulation (21 CFR Part 803), please go to https://www.fda.gov/medical-device-safety/medical-device-reportingmdr-how-report-medical-device-problems.
For comprehensive regulatory information about mediation-emitting products, including information about labeling regulations, please see Device Advice (https://www.fda.gov/medicaldevices/device-advice-comprehensive-regulatory-assistance) and CDRH Learn (https://www.fda.gov/training-and-continuing-education/cdrh-learn). Additionally, you may contact the Division of Industry and Consumer Education (DICE) to ask a question about a specific regulatory topic. See the DICE website (https://www.fda.gov/medical-device-advice-comprehensive-regulatoryassistance/contact-us-division-industry-and-consumer-education-dice) for more information or contact DICE by email (DICE@fda.hhs.gov) or phone (1-800-638-2041 or 301-796-7100).
2
Sincerely, Katherine D. Kavlock -S for Brent Showalter, Ph.D.
Assistant Director DHT6B: Division of Spinal Devices OHT6: Office of Orthopedic Devices Office of Product Evaluation and Quality Center for Devices and Radiological Health
Enclosure
3
Indications for Use
Submission Number (if known)
Device Name
CYLOX® ST
Indications for Use (Describe)
The CYLOX® ST implants are interbody fusion devices intended for anterior cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies.
The cervical device is to be used in patients who have had at least six (6) weeks of non-operative treatment. The devices are to be used with autograft bone graft composed of cancellous, cortical, and / or corticocancellous bone and implanted via an anterior approach.
When used as a standalone system, CYLOX® ST is intended to be used as an adjunct to spinal fusion procedures at one level (C3-T1) and must be used with the CYLOX® ST bone screw fixation or connecting plate and must be secured with the corresponding locking screw.
When used with supplemental fixation, such as anterior cervical plates, CYLOX® ST is intended to be used as an adjunct to spinal fusion procedures at one or two levels of the cervical spine (C3-T1).
Type of Use (Select one or both, as applicable)
Prescription Use (Part 21 CFR 801 Subpart D)
Over-The-Counter Use (21 CFR 801 Subpart C)
CONTINUE ON A SEPARATE PAGE IF NEEDED.
This section applies only to requirements of the Paperwork Reduction Act of 1995.
DO NOT SEND YOUR COMPLETED FORM TO THE PRA STAFF EMAIL ADDRESS BELOW.
The burden time for this collection of information is estimated to average 79 hours per response, including the time to review instructions, search existing data sources, gather and maintain the data needed and complete and review the collection of information. Send comments regarding this burden estimate or any other aspect of this information collection, including suggestions for reducing this burden, to:
Department of Health and Human Services Food and Drug Administration Office of Chief Information Officer Paperwork Reduction Act (PRA) Staff PRAStaff(@fda.hhs.gov
"An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB number."
4
Image /page/4/Picture/1 description: The image is a logo for SIGNUS. The logo consists of a stylized letter "S" on the left and the word "SIGNUS" on the right. Below the word "SIGNUS" is the phrase "The Spine Sign" with a horizontal line above and below the phrase. The letter "S" is gray and red.
510(k) Summary
| Applicant: | SIGNUS Medizintechnik GmbH
Industriestrasse 2
D-63755 Alzenau, GERMANY |
|-----------------------------|--------------------------------------------------------------------------------------|
| Date: | 09/30/2024 |
| Contact Person: | Emily Szabo, Ph.D. |
| Contact Telephone: | (216) 452-2658 |
| Contact Fax: | (440) 933-7839 |
| Device Trade Name: | CYLOX® ST |
| Common Name: | Intervertebral body fusion device; |
| Device Classification Name: | Intervertebral Fusion Device With Integrated Fixation, Cervical
(21 CFR 888.3080) |
| Device Class: | II |
| Reviewing Panel: | Orthopedic |
| Product Code: | OVE, ODP |
| Primary Predicate Device: | K201646 - Shoreline® ACS (Anterior Cervical System) |
| Reference Device: | K241438 – SIGNUS TETRIS™ ST, TETRIS™ R ST |
| Device Description: | |
The SIGNUS CYLOX® ST Interbody System is an anterior cervical intervertebral body fusion system. The system is comprised of interbodies, plates, and screws. The interbody device can be used as a standalone implant with screw holes for integrated fixation, or as a construct fixed with a plate and screws. The interbody implants are additively manufactured from titanium alloy (Ti-6Al-4 V ELI). The plates and screws are traditionally machined from titanium alloy (Ti-6Al-4V).
The SIGNUS CYLOX® ST Interbody System is placed in the C3 – T1 spinal region via the Cloward or Smith-Robinson approach. The interbody is available in four different footprints, with multiple heights and angulations. The standalone interbody contains a central holes angulated for fixation with screws into the cranial and caudal vertebral body. The construct interbody contains a central hole and indentation features to mate with the anterior plate.
The device is comprised of structural titanium in an open-pore grid structure. The large fenestration in the implant permits the cage to be packed with autogenous bone graft and/or allograft comprised of cancellous and/or corticocancellous bone graft to facilitate fusion.
Indications for Use and Intended Use:
The CYLOX® ST implants are interbody fusion devices intended for anterior cervical interbody fusion procedures in skeletally mature patients with degenerative disc disease (DDD) of the cervical spine. DDD is defined as discogenic pain with degeneration of the disc confirmed by history and radiographic studies.
5
Image /page/5/Picture/1 description: The image contains the logo for SIGNUS. The logo consists of a stylized letter "S" on the left, with the word "SIGNUS" in bold, black letters on the right. Below the word "SIGNUS" is the tagline "The Spine Sign" in a smaller font, with a horizontal line above it. The stylized "S" is composed of a gray oval shape with red triangles on either side.
The cervical device is to be used in patients who have had at least six (6) weeks of non-operative treatment. The devices are to be used with autograft bone graft composed of cancellous, cortical, and / or corticocancellous bone and implanted via an anterior approach.
When used as a standalone system, CYLOX® ST is intended to be used as an adjunct to spinal fusion procedures at one level (C3-T1) and must be used with the CYLOX® ST bone screw fixation or connecting plate and must be secured with the corresponding locking screw.
When used with supplemental fixation, such as anterior cervical plates, CYLOX® ST is intended to be used as an adjunct to spinal fusion procedures at one or two levels of the cervical spine (C3-T1).
6
Image /page/6/Picture/0 description: The image is a logo for "SIGNUS The Spine Sign". The logo features a stylized letter "S" in gray and red, with the word "SIGNUS" in bold, black letters to the right of the "S". Below "SIGNUS" are the words "The Spine Sign" in a smaller font, underlined with a thin red line.
Summary of Technological Characteristics:
The subject CYLOX® ST has the same intended use and indications for use as the predicate system. The technological characteristics of the subject system are similar to those of the information provided herein demonstrates that any differences do not impact safety or effectiveness.
| Item | Subject Device | Primary Predicate | Equivalence |
|---|---|---|---|
| SIGNUS CYLOX® ST | SeaSpine Shoreline®ACS | ||
| (K201646) | |||
| Classification | |||
| Name | Intervertebral Fusion Device With Integrated Fixation, Cervical; | ||
| Intervertebral Fusion Device With Bone Graft, Cervical | Intervertebral Fusion Device With Integrated Fixation, Cervical; | ||
| Intervertebral Fusion Device With Bone Graft, Cervical | Substantially | ||
| equivalent | |||
| Regulation | 21 CFR 888.3080 | ||
| (Intervertebral Body Fusion Device) | 21 CFR 888.3080 | ||
| (Intervertebral Body Fusion Device) | Substantially | ||
| equivalent | |||
| Product Code | OVE, ODP | OVE, ODP | Substantially |
| equivalent | |||
| Indications for | |||
| Use | The CYLOX® ST implants are interbody fusion devices | ||
| intended for anterior cervical interbody fusion procedures in | |||
| skeletally mature patients with degenerative disc disease (DDD) | |||
| of the cervical spine. DDD is defined as discogenic pain with | |||
| degeneration of the disc confirmed by history and radiographic | |||
| studies. |
The cervical device is to be used in patients who have had at
least six (6) weeks of non-operative treatment. The devices are
to be used with autograft bone graft composed of cancellous,
cortical, and / or corticocancellous bone and implanted via an
anterior approach.
When used as a standalone system, CYLOX® ST is intended to
be used as an adjunct to spinal fusion procedures at one level
(C3-T1) and must be used with the CYLOX® ST bone screw
fixation or connecting plate and must be secured with the
corresponding locking screw.
When used with supplemental fixation, such as anterior cervical
plates, CYLOX® ST is intended to be used as an adjunct to | The Shoreline ACS (Anterior Cervical System) are interbody
fusion devices intended for anterior cervical interbody
fusion procedures in skeletally mature patients with degenerative
disc disease (DDD) of the cervical spine. DDD is defined as
discogenic pain with degeneration of the disc confirmed by
history and radiographic studies. The Shoreline ACS implants
are to be used with autograft bone graft and/or allogeneic bone
graft composed of cancellous, cortical, and / or corticocancellous
bone and implanted via an anterior approach. The device is to be
used in patients who have had at
least six (6) weeks of non-operative treatment.
When used as a standalone system, Shoreline ACS is intended to
be used as an adjunct to spinal fusion procedures at one level
(C2-T1) and must be used with the Shoreline ACS bone screw
fixation and locking cover.
When used with supplemental fixation, such as anterior cervical
plates, the Shoreline Cervical low profile (TruProfile) Interbody | Substantially
equivalent |
7
Image /page/7/Picture/0 description: The image is a logo for "SIGNUS The Spine Sign". The logo has a gray and red graphic on the left side and the text "SIGNUS" on the right side. Below the text is the phrase "The Spine Sign" with a line above and below it.
| Item | Subject Device | Primary Predicate | Equivalence | |
|---|---|---|---|---|
| SIGNUS CYLOX® ST | SeaSpine Shoreline®ACS | |||
| (K201646) | ||||
| spinal fusion procedures at one or two levels of the cervical | ||||
| spine (C3-T1). | Spacer is intended to be used as an adjunct to spinal fusion | |||
| procedures at one or two levels of the cervical spine (C2-T1). | ||||
| Material | Cage: Ti-6Al-4V ELI per ASTM F3001 | |||
| Plate: Ti-6Al-4V ELI per ASTM F136 | ||||
| Screws: Ti-6Al-4V ELI per ASTM F136 | Cage: Polyetheretherketone (PEEK) per ASTM F2026, | |||
| commercially pure titanium per ASTM F67 | ||||
| Plate: Ti-6Al-4V ELI per ASTM F136 | ||||
| Screws: Ti-6Al-4V ELI per ASTM F136 | Substantially | |||
| Equivalent | ||||
| Manufacturing | Cages: additive manufacturing | |||
| Plates: traditional machining | ||||
| Screws: traditional machining | Cages: Traditional molding and/or machining | |||
| Plates: Traditional molding and/or machining | ||||
| Screws: Traditional molding and/or machining | Substantially | |||
| Equivalent | ||||
| Sterilization | Sterile | Sterile | Substantially | |
| Equivalent | ||||
| Implantation | ||||
| Level | C3-T1 | C2-T1 | Substantially | |
| Equivalent |
8
Image /page/8/Picture/1 description: The image is a logo for SIGNUS. The logo consists of a stylized letter "S" in red and gray, followed by the word "SIGNUS" in black, sans-serif font. Below the word "SIGNUS" is the tagline "The Spine Sign" in a smaller font, underlined with a thin red line.
Performance Testing - Non-Clinical:
Substantial equivalence was supported by the results of verification testing to confirm that features, geometry and performance of the subject device performs as well as the predicate system, including:
- Static Axial Compression per ASTM F2077-22 .
- Static Axial Compression Shear per ASTM F2077-22
- . Static Axial Torsion per ASTM F2077-22
- . Dynamic Axial Compression per ASTM F2077-22
- . Dynamic Axial Compression Shear per ASTM F2077-22
- . Dynamic Axial Torsion per ASTM F2077-22
- . Static Expulsion per ASTM F-04.25.02.02
- . Static Subsidence per ASTM F2267-22
Performance Testing - Clinical:
Clinical testing was not applicable to support a substantial equivalence determination for the subject device.
Conclusion
Based on the indications for use, technological characteristics, and comparison with the predicate device, the subject device has demonstrated substantial equivalence.